Page 5 - Ivir News Today

A new preventative vaccine has been developed incorporating technology funded by the NIH since 2004. The trials will be conducted in the United States and South Africa.

Three days after Blue Ridge Rock Fest was canceled, attendees are left wondering when or if they'll get their refunds.

Blue Ridge Rock Festival attendees are calling for refunds after they describe unsanitary conditions, and cancellation.

Vir Biotechnology (NASDAQ:VIR – Get Free Report) and JATT Acquisition (NYSE:JATT – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends. Analyst Ratings This is a breakdown of […]

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) hit a new 52-week low on Tuesday . The stock traded as low as $12.10 and last traded at $12.15, with a volume of 320691 shares trading hands. The stock had previously closed at $12.51. Analysts Set New Price Targets Several equities research analysts have […]

Virginia International Raceway plays host to the IMSA WeatherTech SportsCar Championship's second GT-only race of the year, the Michelin GT Challenge, where 20 GTD PRO and GTD drivers get to slug it out without constantly checking their mirrors for ...

Every first statement, every first question, every first answer, every first reaction. because to be this countrys next president, you only get one first impression. >> the first republican primary debate. martha maccallum and bret, moderate america is watching. >> back in my day, we dont have all of these types of fancy chicken for sure. you have wings and fried chicken. well, we didnt have garlic farm or sweet barbecue and he had to walk uphill both ways. >> and its every time. hydr >> yeah, r...

An annual charity golf tournament organised by VIR in October hopes to bring opportunity to disadvantaged students across the country.

Needham & Company LLC restated their buy rating on shares of Vir Biotechnology (NASDAQ:VIR – Free Report) in a research note released on Friday, Benzinga reports. They currently have a $22.00 price target on the stock. Several other equities research analysts also recently commented on the stock. HC Wainwright reaffirmed a buy rating and set […]

Vir Biotechnology (NASDAQ:VIR – Get Free Report) released its earnings results on Thursday. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.24), Briefing.com reports. The business had revenue of $3.80 million during the quarter, compared to analysts’ expectations of $22.39 million. The company’s quarterly revenue […]